LOGO - COLOR Who We AreOur Leadership Our Leadership The Power of Teamwork Our leaders come from almost every sector of the biopharmaceutical industry, with decades of experience in drug discovery, as well as drug development and commercialization. But, most importantly, they understand the collective power of a team that explores together, asks the tough questions together, and challenges the status quo together. Purposefully, we create powerful relationships within our team and with our partners that will deliver new and better therapeutic options for cancer patients—together. Management Team Board of Directors Scientific Advisory Board Brian Stuglik, RPh, Chief Executive Officer Mr Stuglik was appointed Chief Executive Officer (CEO) of Verastem Oncology in July 2019. Mr Stuglik is a global leader in the oncology pharmaceutical sector, having successfully developed, acquired, and launched several important oncology products across multiple tumor types and therapeutic approaches in his more than 30-year career in US and international pharmaceutical development, product strategy, commercialization, and business development… Read More Dan Paterson, President and Chief Operating Officer Mr Paterson joined Verastem Oncology in 2011 and has served as its Chief Operating Officer since 2014. He has more than 30 years of experience at healthcare and biotechnology companies, including leadership roles as Chief Business Officer (CBO), Chief Operating Officer (COO) and Chief Executive Officer (CEO), with specific expertise in oncology drug and diagnostic product development, business development, and launch planning… Read More Rob Gagnon, Chief Business and Financial Officer Mr Gagnon joined Verastem Oncology as Chief Financial Officer in August 2018. Mr Gagnon brings a great deal of financial and commercial experience in heading global finance operations. Before joining Verastem, Mr Gagnon was Chief Financial Officer at Harvard Bioscience, Inc, a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine. Prior to this, he served as Executive Vice President, Chief Financial Officer,… Read More Cathy Carew, Chief Organizational Effectiveness Officer Ms Carew has been with Verastem Oncology since 2012, bringing nearly 20 years of management and consulting experience in the biopharma industry, assisting companies in transition from research stage to development stage to commercial stage. Most recently, she served as the part-time Head of Human Resources at Verastem Oncology, … Read More Jonathan Pachter, PhD, Chief Scientific Officer Dr Pachter brings over 30 years of experience in leading discovery and translational research for small molecule and monoclonal antibody anti-cancer therapeutics. He was previously Head of Cancer Biology at OSI Pharmaceuticals, where his team was responsible for development of models of tumor cell EMT (epithelial-mesenchymal transition) and discovery of drugs disrupting this process. At OSI, he advanced five small molecules into development for treatment of cancer, including OSI-906—a selective IGF-1R/insulin receptor kinase inhibitor… Read More Louis Denis, MD, Chief Medical Officer Dr Denis was appointed Chief Medical Officer in September 2021. Dr Denis is a medical oncologist and brings to Verastem more than 25 years of academic and industry experience in clinical cancer drug development. Prior to joining Verastem, Dr Denis was the Chief Medical Officer of Asana BioSciences where he provided strategic direction as well as medical and safety oversight to Asana’s portfolio of oncology and immunology… Read More Hagop Youssoufian, MSc, MD, Head of Medical Strategy Dr Youssoufian served as Chief Medical Officer at BIND Therapeutics. Prior to BIND, he was Executive Vice President at Progenics Pharmaceuticals and President, Research & Development and Chief Medical Officer at Ziopharm Oncology. Before joining Ziopharm, Dr Youssoufian served as Chief Medical Officer and Senior Vice President, Global Clinical Sciences at Imclone Systems. Prior to Imclone, he served in leadership positions at Sanofi Aventis and Bristol-Myers Squibb. Earlier in his career… Read More Our Culture Contact Sign Up for Alerts Terms of Use Copyright Statement Privacy Policy Contact © 2021 Verastem, Inc. All Rights Reserved.